Management Profiles

Bala Venkataraman, CEO

William Campbell, VP, CFO

Connie Swanson, VP, Sales and Marketing

Virinder Nohria, Chief Medical Officer

Bala Venkataraman was previously Chief Operating Officer (2002- 2003), Chief Financial Officer (1999- 2002), VP Business Development, Strategic Planning and Operations (1998 -2000) at First Horizon Pharmaceutical Corporation. Bala was responsible for growing the company from an operating loss and sales of approximately $5M, to, at its peak, an operating profit of approximately $14M and sales of approximately $115M in 5 years. In addition, Bala was responsible for in-licensing or acquiring over 15 drugs, commercializing 8 products, concluding 5 co-promotion agreements, and developing the company’s product pipeline through partnerships with contract manufacturers, research organizations and drug development companies. He successfully took the company public and raised in excess of $500M in debt and equity capital, and built the company employee base from approximately 70 people to approximately 300 people. Bala’s previous experiences includes: venture capitalist in managing specialty pharmaceutical and biotechnology investments for EJ Financial (Neopharm, First Horizon Pharmaceutical, ProtoMed), product management at Schering-Plough (oncology drug Intron^®A), Licensing and New Business Start-up, at the University of Pennsylvania Center for Technology Transfer, Marketing Manager at Curative Technologies Inc. (marketing of wound care services and launch of autologous growth factor Procuren^®), Technical Sales Representative for Millipore Corporation (purification equipment to pharmaceutical companies), Senior Research Chemist at Scios Inc. (cardiovascular and inflammation product development). Bala has an M.S. degree in Organic Chemistry from Case Western Reserve University and an M.B.A. degree from the Wharton School of Business. Bala has several research publications, holds three patents and has several patent applications pending. He is a member of the Licensing Executives Society.

William (Bill) Campbell was previously Controller (1998 - 2003), Treasurer (1999 - 2003) and VP of Administration (2002 - 2003) at First Horizon Pharmaceutical Corporation. At First Horizon, Bill was responsible for all aspects of the finance function, including inventory management, budgeting, managing the cash flow, product acquisition, debt and equity financing, operationalizing the sales force and managing human resources. Bill was critical in making the company profitable and successfully sustaining the profits, completing a successful IPO with limited equity financing prior to the IPO, helping raise over $350M in equity and $150M in debt, managing over 50 operating agreements, managing 12 manufacturers and over 40 product SKUs, and operating the company under high leverages. Prior to joining First Horizon, from 1995 to 1998, Bill was the Controller/Chief Financial Officer of Dialysis America, Inc. and was responsible for the successful and profitable sale of the company to Fresinius. He was the Associate Administrator/Chief Financial Officer of Stringfellow Memorial Hospital from 1993 to 1995, and from 1989 to 1993, was the Director of Budgets, Costs and Reimbursement at Grady Memorial Hospital. His prior professional experience also includes a number of for-profit and not-for-profit consulting, big four public accounting, governmental auditing and internal audit positions. Bill is a Certified Public Accountant. He received a B.A. degree in Accounting from Walsh College of Accountancy and Business Administration, and an M.B.A. degree in Accounting from Kennesaw State College.

Connie Swansonwas previously Senior Director of Marketing (1999 - 2001) and National Sales Trainer (1996 - 1999) at First Horizon Pharmaceutical Corporation. Connie was responsible for hiring, training, deploying and successfully leading a significant majority of the First Horizon sales force and sales management during several sales force expansions prior to 2001. In addition, as head of Marketing, Connie launched several of First Horizon’s key brands including Ponstel^® (Women’s Health), Zebutal^® (Tension Headache), Nitrolingual Pumpspray^® (Cardiology), Robinul^® (Gastroenterology) and Tanafed^® (Pediatric) while leading a team of product managers. Connie was also instrumental in the selection and acquisition of three of First Horizon’s key products, Robinul^®, Ponstel^® and Nitrolingual^® Pumpspray. She was the Company’s top producing sales representative and district manager during its formative years (1993 - 1995). Connie earned a B.S. degree in Chemistry from North Georgia College and State University and worked as a pharmacy technician while obtaining her degree.

Virinder Nohria was previously the Chief Medical Officer of Xcel Pharmaceutical (2004-2005) and Chief Medical Officer of DevCo Pharmaceutical (1999-2003). He was a Senior Research Physician for UCB Pharma and Global Physician, Neurology Division, for Eli Lilly and Company. Dr. Nohria was responsible for the development and approval of Keppra^® and Permax^®. He was also part of the team that was responsible for the development and approval of Zyprexa^®. Dr Nohria has eight years of clinical practice in the area of pediatric neurology in both the United Kingdom and the United States. Dr. Nohria was an Assistant Professor of Pediatrics and Neurology at University of Virginia and is currently an Assistant Professor at the Emory School of Medicine. He earned his medical degree at Cambridge University and his Ph.D. at Leeds University.